Seventeen research firms currently cover Jazz Pharmaceuticals, awarding the stock an average rating of “Moderate Buy.” Of those, thirteen analysts have issued buy recommendations, three have held, and one has rated it a sell. Over the past year, the average 12-month price objective among these brokers stands at $205.67. Notable recent updates include JPMorgan Chase & Co. trimming its objective to $199 while maintaining an overweight view; Truist Financial raising its target to $230 with a buy rating; Robert W. Baird lifting its objective to $209 with an outperform designation; and Royal Bank of Canada setting its target at $194 alongside an outperform rating.

Insiders have been net sellers over the past quarter, offloading a combined 123,791 shares valued at approximately $21.99 million. Director Heather Ann McSharry disposed of 3,415 shares in late November for proceeds of $607,118.70, reducing her holding by 14.31%. Chief Accounting Officer Patricia Carr sold 4,660 shares in early December, generating $797,792 and cutting her stake by 39.92%. Company insiders now collectively own 4.30% of outstanding shares.

Institutional investors and hedge funds hold 89.14% of Jazz Pharmaceuticals’ equity. In the third quarter, EverSource Wealth Advisors increased its position by 9.0% to 983 shares, Tectonic Advisors by 1.5% to 5,626 shares, and Fairbanks Capital Management by 0.4% to 25,023 shares. During the second quarter, the Teacher Retirement System of Texas added 90 shares to reach 15,560, while Generali Investments Towarzystwo Funduszy Inwestycyjnych acquired 100 more for a total of 1,250 shares. These modest adjustments reflect continued confidence among large holders in Jazz’s long-term prospects.